Inmune Bio (INMB) Preferred Stock Liabilities (2023 - 2024)

Inmune Bio (INMB) posted Preferred Stock Liabilities of $799000.0 for Q2 2024, little changed sequentially from $799000.0 in Q1 2024.

Inmune Bio (INMB) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends

Inmune Bio has reported Preferred Stock Liabilities for 2 years, with the latest figure at $799000.0 in Q2 2024.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $799000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $799000.0 (changed N/A YoY) and the FY2023 annual result came in at $799000.0, changed N/A from the prior year.
Preferred Stock Liabilities steadied at $799000.0 in Q2 2024 per INMB's latest filing, from $799000.0 in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $799000.0 in Q3 2023 and troughed at $799000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Inmune Bio	61.59 Mn	43.18 Mn	-	-

Download Data